New European Hypertension Guidelines Contrast with American Recommendations

The European guidelines on hypertension have been updated and now feature differences compared with American guidelines regarding how to diagnose and treat patients with high blood pressure. The main difference particularly lies in how aggressive physicians should be in lowering blood pressure. These data are available from a preview of the document presented at the Meeting on Hypertension in Barcelona, soon to be formally published. Many of the recommendations do not match those in American guidelines.

Las nuevas guías Europeas de Hipertensión contrastan con las AmericanasTwo of the major changes in the guidelines from the European Society of Cardiology (ESC) and European Society of Hypertension (ESH) are an emphasis on using at least two drugs to initiate treatment in the vast majority of patients and on using single-pill drug combinations to improve compliance (which ultimately improves blood pressure control).

 

European specialists expect a phenomenal impact (of single-pill combinations), which might bring about 80% of patients under control.


Read also: New High Blood Pressure Guidelines.


Facilitating this approach, specialists selected the three major categories of drugs to treat most patients: renin-angiotensin system blockers, calcium channel blockers, and diuretics. Finally, simple algorithms have been provided to help guide clinicians and general practitioners, who are not trained as cardiologists.

 

Experts hope to make a significant dent in the global burden of this disease by using an approach different than that in American guidelines. Instead of going aggressively after figures, lowering thresholds, this approach focuses on simplifying treatment so that everyone can receive it and comply with it.

 

These guidelines will be fully and formally published next August at the ESC Congress in Munich, Germany, and key differences are expected regarding the American guidelines published last year.


Read also: Baseline Pulmonary Hypertension Should Not Preclude TAVR.


Europeans maintained traditional categories, with grade 1 hypertension starting at 140/90 mmHg, whereas Americans lowered that threshold to 130/80 mmHg. For Europeans, the large group of patients in that threshold should receive lifestyle advice to reduce their risk, but they should neither be called ‘hypertensive’ nor receive medication.

 

Patients in this 130 to 139 mmHg range should be treated only if they have documented cardiovascular disease or an estimated 10-year risk of at least 10%.

 

American guidelines recommend a target blood pressure below 130/80 mmHg for everybody. Alternatively, Europeans also recommend a target of 130 mmHg, but not lower than 120 mmHg for people younger than 65 years old. For people over 65, even those who present comorbidities, the target is less than 140 Hg, but not lower than 130 mmHg. In all cases, the first priority is to get below 140 mmHg. The idea of taking elderly patients below 130 mmHg, as put forward by Americans, is considered as too aggressive by Europeans.

 

However, all of them coincide in their emphasis on lifestyle changes (stopping smoking, eating less salt, moderating alcohol consumption, getting more exercise, and maintaining an appropriate body weight). All those measures are essential, although most patients will still need pharmacological medication.

 

Original title: 2018 ESC/ESH Guidelines for the Management of Arterial Hypertension.

Reference: Williams B et al. Presented at: 28th ESH Meeting on Hypertension and Cardiovascular Protection. 2018. Barcelona, Spain.


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

We are interested in your opinion. Please, leave your comments, thoughts, questions, etc., below. They will be most welcome.

More articles by this author

ACVC 2026 | CELEBRATE Trial: Prehospital Zalunfiban Use in STEMI

Optimizing antithrombotic therapy in the prehospital phase of ST-segment elevation myocardial infarction (STEMI) remains challenging due to the delayed onset of action of P2Y12...

Drugs for the Treatment of No-Reflow During PCI

The no-reflow phenomenon is one of the most frustrating complications of primary angioplasty (pPCI), reflecting persistent microvascular damage that, in the mid- to long-term,...

CRT 2026 | Clopidogrel vs Aspirin as Long-Term Monotherapy After Coronary Angioplasty

The use of aspirin as chronic antiplatelet therapy after percutaneous coronary intervention (PCI) has historically been the standard recommended by international guidelines. However, recent...

Low-Dose Rivaroxaban After Peripheral Angioplasty: Effectiveness and Safety in Real-World Clinical Practice

Following lower limb revascularization, optimal medical therapy includes antiplatelet agents, high-intensity statins, and control of cardiovascular risk factors. Recent studies such as COMPASS and...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

ACVC 2026 | CELEBRATE Trial: Prehospital Zalunfiban Use in STEMI

Optimizing antithrombotic therapy in the prehospital phase of ST-segment elevation myocardial infarction (STEMI) remains challenging due to the delayed onset of action of P2Y12...

ACVC 2026 | BOX Substudy: Mean Arterial Pressure Targets in Cardiogenic Shock After OHCA

Hemodynamic management of cardiogenic shock following ischemic out-of-hospital cardiac arrest (OHCA-AMICS) remains an unresolved issue, particularly regarding optimal mean arterial pressure (MAP) targets and...

ACVC 2026 | FLASH Registry European Cohort: Mechanical Thrombectomy in Pulmonary Embolism

The management of intermediate-high and high-risk pulmonary embolism (PE) remains an area of therapeutic uncertainty, particularly in patients with right ventricular (RV) dysfunction, in...